ERBB2 and posterior cortical atrophy: Collectively, the results presented in these prior studies (i.e., molecular mechanisms promoting AR activity in HER2-high tumor cells) reflect years of prolonged ADT for recurrent PCa, such that the therapeutic window for cotargeting HER2 and AR would have been lost.